Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

Launched by CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH · Jun 3, 2021

Keywords

ClinConnect Summary

This clinical trial is about creating a collection of blood samples to help researchers study stem cell transplantation and other cellular therapies. The goal is to understand more about how these treatments work and why some patients have better outcomes than others. Researchers will use these samples to analyze genetic information and learn about different tissue types in various populations, which can improve future treatments for patients receiving stem cell transplants or dealing with marrow toxic injuries.

Individuals who may be eligible to participate include donors who have given or will give stem cells for transplantation, patients who have received a stem cell transplant, and those treated for marrow toxic injuries at specific centers. This includes both adults and children, regardless of their ability to make decisions about their care. Participants can expect their blood samples to be used anonymously for important research, which could lead to advancements in treatment options for many patients in the future.

Gender

ALL

Eligibility criteria

• Eligibility to participate in the Research Sample Repository Protocol:
• • Hematopoietic Cell (HC) or Other Cellular Therapy Donors
• • Donors are eligible to participate in the Research Sample Repository if they have donated or are scheduled to donate HCs or cellular therapy products to an allogeneic recipient either by a marrow harvest or by apheresis. This includes adults with and without decision making capacity and children.
• • All donors registered on the National Marrow Donor Program (NMDP) Registry, regardless of whether they have been requested to donate a product for a patient, are eligible to participate in the Research Sample Repository.
• • Cord Blood Units (CBUs)
• • Testable material from CBUs (Specimens) infused at treatment centers covered under the C. W. Bill Young Transplantation Program are eligible for inclusion in the Research Sample Repository. Material may be submitted by participating treatment centers, centralized laboratories and Cord Blood Banks.
• • Hematopoietic Cell Transplantation or Other Cellular Therapy Recipients
• • All U.S. recipients of allogeneic or autologous HC transplants or cellular therapies are eligible to participate in the Research Sample Repository. This includes adults with and without decision making capacity and children.
• • Patients with Marrow Toxic Injury
• • Any patient who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Treatment Network (RITN) is eligible to participate in the Research Sample Repository. This includes adults with and without decision-making capacity and children.
• • Eligible patients may have received support care only, growth factor support, hematopoietic stem cell transplant or other appropriate medical treatment for marrow toxic injury